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Abstract
RhoA is a critical signaling molecule regulating a variety of cellular processes, such as cytoskeletal organization,
adhesion, and apoptosis. It is recently considered responsive to reactive oxygen species (ROS). Nevertheless, how
RhoA regulates anoikis, a detachment-initiated apoptosis, and how this regulation is affected by ROS are not clear.
The present study investigated the role of RhoA in apoptosis/anoikis in gastric cancer cells and the changes of
RhoA and anoikis under oxidative stress. Immunohistochemistry showed that RhoA expression was upregulated
in the primary gastric carcinoma compared with normal gastric mucosa. Overactivation of RhoA by transfection
with the V14RhoA mutant prevented gastric cancer line SGC-7901 cells from arsenic-induced apoptosis and con-
ferred anoikis resistance through, at least in part, promoting formations of F-actin fibers and focal adhesion. Ox-
idative stress caused by emodin, an ROS producer, in combination with arsenic trioxide (ATO) led to RhoA
inactivation that triggered structural disruption of focal adhesion complex and eventually resulted in anoikis, and
these effects could be partially reversed by antioxidant N-acetylcysteine (NAC). In conclusion, activation of RhoA is
required for the maintenance of anoikis resistance phenotype of gastric cancer cells, and oxidative stress might be
a therapeutic strategy for the inhibition of RhoA in cancer cells.
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Introduction
Rho family GTPases serve as critical molecular coordinators in regu-
lating various cellular behaviors. In their active GTP-bound form,
Rho proteins bind to effector proteins, thereby triggering numerous
cellular events, from cell adhesion and migration to cell survival,
death, and transcriptional regulation. Each of these events is of im-
portance for the development and progression of cancer [1–5].
Although Rho genes have never been found mutated in human
tumors [2], the high incidence of overexpression of various Rho fam-
ily members in a spectrum of human cancers suggests that these
proteins are involved in cancer [2,6]. There are three Rho isoforms
(RhoA, RhoB, and RhoC) in mammals [5]. RhoA has been found
overexpressed or overactivated in breast cancer, bladder cancer,
ovarian cancer, and other cancers [7–10]. Active RhoA promotes
transcriptional activation of AP-1 and NFκB and regulates the acti-
vation of cyclin D1, p21cip1, and p27kip1 [11–13]. Thus, the role of
RhoA in cancer is likely attributed to prosurvival and antiapoptosis.
Paradoxically, RhoA is also a signaling mediator in the morpho-
logic changes associated with apoptosis through its effects on actin
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polymerization and actomyosin contractility. Introduction of a con-
stitutively activated form of RhoA is sufficient for cell contraction
and membrane blebbing that are the necessary events of apoptosis
[3]. The RhoA effector protein ROCK acts in plasma membrane
blebbing of apoptotic cells through activated myosin light chain
which promotes actin filaments polymerization and regulates the ac-
tomyosin contractility [14,15]. Therefore, the role of RhoA in apo-
ptosis remains to be clarified.
Loss of cell–extracellular matrix (ECM) contacts results in cell death
by apoptosis, a phenomenon known as anoikis, or detachment-
induced apoptosis [16]. All the features that characterize apoptosis
are also observed during anoikis, such as caspases’ activation and nu-
clear fragmentation [17]. The interest in understanding the molecu-
lar mechanisms of anoikis has increased significantly during the last
few years as it becomes evident that resistance to anoikis is a critical
requirement for survival, invasion, and metastasis of cancers derived
from epithelial cells [18]. Despite the increasing interest in the study
of anoikis, the basic mechanisms of this phenomenon are still poorly
understood [16,19]. A better understanding of anoikis could have an
impact on the development of novel therapies for cancer, because
it has been demonstrated that the reversion of anoikis resistance in-
hibits tumor progression [20]. Focal adhesion sites are specific areas
on the cell membrane where cells attach to ECM. They are com-
plexes of structural and signaling proteins, anchoring actin filaments
and microtubules to the plasma membrane where integrins locate
[21]. Most integrin β-subunits interact with proteins, such as paxil-
lin, talin, vinculin, and other focal adhesion proteins, which act as
linkers between integrins and the actin cytoskeleton [22–24]. It
has been known that key players in integrin-mediated signal trans-
duction are a group of integrin-associated nonreceptor kinases, two
of them being focal adhesion kinase (FAK) and integrin-linked kinase
(ILK), which may render influence on anoikis [21,25–28]. Because
integrity of the focal adhesion complex depends on the actin cyto-
skeleton and their associated proteins, we may wonder the plausible
role of RhoA in regulating anoikis. However, there has been little
documentation in this regard.
Arsenic trioxide (As2O3 or ATO), a novel chemotherapeutic agent
for treating acute promyelocytic leukemia, induces apoptosis of tu-
mor cells with dependence on the cellular reactive oxygen species
(ROS) [29,30]. In our previous studies, we have found a dramatic
actin cytoskeleton change in gastric cancer cells exposed to ATO (da-
ta unpublished), and that the generation of ROS by emodin (6-
methyl-1,3,8-trihydroxyanthraquinone) can sensitize some solid tu-
mor cells to ATO-induced apoptosis [31–33]. Recently, RhoA was
considered responsive to ROS and redox state [34,35]. These have
raised questions on how RhoA functions in cancer cells apoptosis/
anoikis and how this function is regulated by oxidation/reduction
(redox) state of cells.
We herein report that RhoA plays an antiapoptotic role in gastric can-
cer cells through promoting the resistance of anoikis. Moreover, oxidative
stress caused by emodin in combination with ATO can inhibit RhoA ac-
tivation to sensitize human gastric carcinoma SGC-7901 cells to an-
oikis by disordered F-actin assembly and vinculin distribution.
Materials and Methods
Cell Culture, Reagents, and Treatments
Human gastric cancer line SGC-7901 cells [36,37] were cultured
in Dulbecco’s modified Eagle’s medium (DMEM; Gibco BRL,
Gaitherburg, MD), supplemented with 100 U/ml penicillin, 100 mg/
l streptomycin, and 10% fetal bovine serum, and were maintained
at 37°C in a humidified incubator with 5% CO2. Arsenic trioxide
(ATO or As2O3), emodin, and N-acetylcysteine (NAC) were pur-
chased from Sigma (St. Louis, MO). Cells were exposed to various
treatments for indicated times. ATO was used alone at 5 μM or in
combination with emodin. To achieve a synergistic cytotoxic effect
with arsenic, emodin was added at 10 μM, at which dose emodin
alone had no cytotoxicity, according to our previous studies [31].
To assess the role of ROS, cells were pretreated with antioxidant NAC
at 10 mM 4 hours before the above treatments, whenever it was used.
Immunohistochemistry
The human tissue samples were collected using institutionally ap-
proved protocols, in which 10 normal gastric tissues were derived
from pathologic autopsy and 60 gastric carcinoma tissues were ar-
chived pathologic specimens in Ren Ji and Rui Jin Hospitals and were
paraformaldehyde-fixed and paraffin-embedded specimens. A poly-
clonal mouse anti–human RhoA antibody (Ab) (Santa Cruz Biotech-
nology, Santa Cruz, CA) was incubated with the sections overnight at
4°C followed by biotinylated secondary Ab. Immunohistochemical re-
actions were visualized by the peroxidase-conjugated streptavidin, for
which DAB was used as a chromagen. The results were analyzed using
an image analysis software (QWin Plus; Leica Microsystems, Wetzler,
Germany). The positivity rate was scored based on the percentage of
the cells positive for RhoA in total cancer cells [38,39]. (−) indicates
that the positive cells were <10%; (+), 10% ∼ 50%; and (++), >50%.
RhoA Constructs’ Transfection
SGC-7901 cells were transfected with the wild-typed and mutated
RhoA to determine the impact of RhoA on cell behaviors. Actively
growing cells were transiently transfected with the wild-typed and
site-mutated RhoA constructs, V14RhoA, the constitutively activated,
and N19RhoA, the dominant-negative mutants (kindly provided
by Dr. Richard D. Ye, University of Illinois at Chicago) [40,41].
Transfection was performed using a reagent (Lipofectamine 2000; In-
vitrogen, Carlsbad, CA) in accordance with the manufacturer’s recom-
mendation. Cells were then assayed for various purposes at 40 hours
posttransfection. For all assays involving transfected cells, transfection
efficiency was first checked and confirmed at 30% ∼ 40%.
Soft Agar Clonogenesis
Anchorage-independent growth as a characteristic of in vitro tu-
morigenicity was assessed by soft agar clonogenesis assay. Briefly,
SGC-7901 cells were transiently transfected for 40 hours and were
then trypsinized and mixed with DMEM containing 0.3% agar.
Cell–agar mixture was plated on a 0.5% agar underlay (1 × 103
per well in six-well plates) and allowed to grow for 2 weeks. When
cells needed drug treatment, they were exposed to various treatments
for 9 hours and rinsed before being seeded. The assay was performed
in triplicate for each group. Colony was identified when more than
50 cells grew within it. Calculation was based on the colony number
of the whole well.
Apoptosis Assay
In the early apoptosis, phosphatidylserine, normally located in the
inner leaflet of the plasma membrane, translocates to the outer mem-
brane. In the present study, cells were treated with the indicated
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drugs for 48 hours. After washing once with ice-cold PBS, cells were
collected and stained using an Annexin V–fluorescein isothiocyarate
(FITC)/propidium iodide (PI) kit (BD Pharmingen, San Diego, CA),
in which Annexin V bound to exposed phosphatidylserine of the early
apoptotic cells, whereas PI stained the cells that had an increased mem-
brane permeability, i.e., the late apoptotic cells. Samples were prepared
according to the manufacturer’s instruction and analyzed by flow cy-
tometry on a FACS Calibur (Becton Dickinson, San Diego, CA).
ROS Detection
2,7-Dichlorodihydrofluorescein diacetate (DCFH-DA, Sigma)
was used as ROS capture in the cells. It is cleaved intracellularly
by nonspecific esterases to form 2,7-dichlorodihydrofluorescein
(DCFH), which is further oxidized by ROS and becomes a highly
fluorescent compound 2,7-dichlorofluorescein (DCF). In the present
study, SGC-7901 cells were transiently transfected for 40 hours and
were then exposed to various drugs for the indicated times. DCFH-
DA at 10 μM was coincubated with cells for 20 minutes. After wash-
ing once with ice-cold PBS, cells were harvested and kept on ice for
an immediate detection by flow cytometry. The average intensity of
DCF stands for intracellular ROS levels.
Western Blot
SGC-7901 cells were lysed in a lysis buffer. Proteins were separated
on 12% polyacrylamide gels and were transferred to nitrocellulose
membranes. The blots were then incubated with first Ab, mouse anti–
human Ab, followed by a peroxidase-conjugated second anti–mouse Ab
(Promega, Madison, WI). Enhanced chemiluminescence (Amersham,
Freiburg, Germany) was used for detection.
Immunofluorescence for RhoA and Vinculin, and Fluorescence
for F-Actin
Cell monolayers on cover slides were fixed by 4% paraformal-
dehyde, permeated in 0.2% Triton X-100 at 4°C, and blocked with
5% BSA before double labeling for RhoA/vinculin, RhoA/F-actin, or
F-actin/vinculin. Cell monolayers were incubated with the mouse anti–
human vinculin (1:50; NeoMarkers, Fremont, CA) or mouse anti–
human RhoA (1:50; Santa Cruz Biotechnology, CA) Ab at 4°C for
overnight. Subsequently, the cells were incubated with rhodamine- or
FITC-conjugated anti–mouse Ab (1:200; SouthernBiotech, Birming-
ham, AL) for 2 hours at 37°C separately and, when needed, coincu-
bated with rhodamine–phalloidin (Sigma) for 40 minutes. Then the
slides were examined under a laser confocal microscope (LSM510;
Zeiss, Oberkochen, Germany).
RhoA Pull-Down Assay
Recombinant protein for Rhotekin Rho binding domain (RBD)
can specifically bind to and precipitate GTP-, not GDP-formed Rho
from cell lysates. RBD is linked to GST-coated agarose beads to form
GST-RBD (Upstate, Lake placid, NY). Cells were treated with the in-
dicated drugs for 9 hours before being lysed with buffers and methods
as the manufacturer recommended. The lysate was incubated with
40μg of GST-RBD for 1 hour. After binding, the samples were washed
with lysis buffer three times. Pulled-down proteins that are activated
Rho were fractionated on 12% SDS-PAGE and immunoblotted with
polyclonal Ab against RhoA (Santa Cruz Biotechnology). The total
cell lysates were also blotted with Ab for RhoA as a loading control.
The level of activated RhoA was determined after normalization with
the total RhoA present in the same cell lysates.
Caspase-3 Activity Assay
Caspase-3 activity was determined using the caspase-3 assay kit (BD
Pharmingen) according to the manufacturer’s instructions. This assay
depends on the activity of cleavage of a specific caspase-3 substrate
N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (Ac-DEVD-
AMC) to liberate fluorescent AMC. After various treatments, cells were
collected by scraping in cold PBS, centrifuged (at 800g for 5 minutes),
and lysed in the cell lysis buffer provided in the kit on ice for 30 min-
utes. Extracts were mixed with an equal volume of 2× reaction buffer
containing the Ac-DEVD-AMC and left for reaction in a water bath at
37°C for 60 minutes. The fluorescence intensity of liberated AMC,
positively proportional to the caspase-3 activity, was measured using a
plate reader with an excitation wavelength of 380 nm and an emission
wavelength range of 420 to 460 nm.
Statistics
SPSS 13.0 software package (SPSS Inc., IL) was used for statistical
analysis. Chi-square test was applied for enumeration data. Analysis of
variance (ANOVA) was applied for comparison of the means of two or
multiple groups of measurement data, in which Student-Newman-Keuls
(SNK) test was used for further comparison of each group. For all of the
value differences, P < .05 was considered significant.
Results
RhoA Was Overexpressed in Gastric Carcinoma Tissues, and
the Level of Expression Was Positively Related to Malignancy
RhoA expression was examined in human normal gastric tissues and
gastric carcinoma tissues by immunohistochemistry. In general, RhoA
was undetectable in normal gastric mucosa, only showing positive in a
few of cells mainly in the gastric pits in 20% specimens of nontumor
tissues and 10% ones of normal mucosa adjacent to tumors. RhoA
expression was largely positive in gastric carcinoma cells (85%). The
value difference was considered significant between gastric carcinoma
and normal gastric mucosa/benign tissue adjacent to the tumor (P <
.05). In addition, the expression was more predominant in lowly dif-
ferentiated carcinomas. The values for the strong positivity (++) were
significantly different between lowly and highly differentiated gastric
carcinoma, as well as between moderately and highly differentiated
gastric carcinoma (P < .05) (Figure 1 and Table 1).
Overexpression or Overactivation of RhoA in SGC-7901 Cells
Antagonized Apoptosis
After SGC-7901 cells were transfected with different doses of
wild-typed RhoA, the expression of RhoA was increased in a dose-
dependent manner. RhoA obviously rescued ATO-induced apoptosis
in a dose-dependent manner (Figure 2A and Figure W1). Likewise,
in SGC-7901 cells transfected with the vector, the constitutively acti-
vated mutant V14RhoA, and the dominant negative one N19RhoA,
the activated RhoA was capable of antagonizing apoptosis induced by
ATO treatment, compared to the normal and inactivated RhoA, al-
though the antiapoptosis function of RhoA was not apparent before
ATO treatment (Figure 2B and Figure W1).
RhoA Activation Rendered SGC-7901 Cells’ Anoikis Resistance
To determine whether RhoA overactivation rescued SGC-7901
cells through inhibiting anoikis, a classic assay, colony formation in
soft agar, was performed. A more potent capacity of colony formation
derived from single cell in soft agar represents an increased resistance
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to anoikis [42]. Results showed that the colonies in the V14RhoA-
transfected cells were obviously more numerous than in the mock-
and N19RhoA-transfected cells (Figure 3). This result suggested that
RhoA activation rendered cells’ anoikis resistance, which might ac-
count for, at least partially, the capability of antiapoptosis in SGC-
7901 cells.
RhoA Activation Altered Assembly of F-Actin and Distribution
of Vinculin
In the V14RhoA- and N19RhoA-transfected SGC-7901 cells,
immunofluorescence was performed for visualizing the expression
and distribution of RhoA and vinculin, and rhodamine–phalloidin
staining was performed for visualizing F-actin. In the V14RhoA-
transfected cells where RhoA was overexpressed and overactivated,
F-actin was shown with a tremendously high intensity and was in
concentrated bundles. In contrast, F-actin was hardly detectable in
the N19RhoA-transfected cells where RhoA was overexpressed but
inactivated (Figure 4A). Obviously, owing to reorganization of the
actin fibers, the V14RhoA-transfected cells appeared more spread
and thus larger, whereas the shape of N19RhoA-transfected cells
was shrunk and highly irregular. Normally, vinculin was evenly dis-
tributed over the whole cytoplasm, but spottily concentrated to the
plasmic membrane where the focal adhesion sites formed, as seen in
cells transfected with mock DNA. However, in cells expressing RhoA
mutants, the distribution of vinculin was changed. Compared with
the mock DNA–transfected cells, the fluorescence of vinculin in
V14RhoA cells aggregated into coarser plaques at the periphery of
the cells, indicating that the focal adhesion was abnormally strength-
ened, whereas in N19RhoA cells, it was dispersed and much weaker,
and the adhesive spots were nearly disappeared (Figure 4B). Notably,
Western blot analysis showed that the quantities of vinculin and actin
were not changed in cells, whether RhoA was overexpressed and ac-
tivated or not (Figure 4C ). These data indicated that overactivation
of RhoA in SGC-7901 cells could enhance assembly of the actin fila-
ments, and meanwhile enhance the cell attachment by simulta-
neously changing the distribution of vinculin, which could explain
RhoA-mediated resistance to anoikis.
Oxidative Stress Caused by Emodin in Combination with
Arsenic Enhanced Apoptosis, By Suppressing the Activation of
RhoA, but not Downregulating the Expression of Total RhoA
According to our previous studies, emodin, an ROS producer, can
enhance cytotoxicity of the various drugs by inducing a high oxida-
tive stress [31–33]. We therefore examined the effect on relative ROS
Figure 1. RhoA was overexpressed in gastric carcinoma tissues, and the level of expression was related to malignancy (peroxidase–DAB
immunohistochemistry): (A) normal gastric mucosa, (B) highly differentiated gastric carcinoma, (C) moderately differentiated gastric
carcinoma, and (D) lowly differentiated gastric carcinoma (original magnification, ×200).
Table 1. RhoAWas Overexpressed in Gastric Carcinoma Tissues, and the Degree of the Positive
Expression Was Related to Malignancy.
Specimens (−) (+) (++)
Nontumor tissue (n = 10) 8 (80%) 2 (20%) 0
Normal tissue adjacent to the tumor (n = 40) 36 (90%) 4 (10%) 0
Highly differentiated gastric carcinoma (n = 20) 4 (20%) 14 (70%) 2 (10%)
Moderately differentiated gastric carcinoma (n = 25) 3 (12%) 14 (56%) 8 (32%)
Lowly differentiated gastric carcinoma (n = 15) 2 (13%) 7 (47%) 6 (40%)
The positivity rate was scored based on the percentage of the cells positive for RhoA in total cancer
cells. (−) indicates that the positive cells were <10%; (+), 10% ∼ 50%; (++), >50%. Chi-square
analysis was applied. The value difference was considered significant between gastric carcinoma and
normal gastric mucosa/benign tissue adjacent to the tumor when P < .05. The values for strong
positivity (++) were significantly different between lowly and highly differentiated gastric carci-
noma, as well as between moderately and highly differentiated gastric carcinoma, when P < .05.
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level and RhoA activation under oxidative stress caused by emodin in
combination with ATO in native SGC-7901 cells. The quantity of
the activated form of RhoA was determined by GST–RBD pull-
down assay in which activated RhoA was isolated. The results showed
that the ROS generation was rapidly and obviously increased in cells
exposed to the combinative treatment (Figure 5A). In parallel, acti-
vation of RhoA is remarkably suppressed a bit later by this oxidative
stress, whereas the expression of total RhoA remained stable (Fig-
ure 5B). These effects could be completely or partially reversed by
the antioxidant NAC (Figure 5).
We then examined if the combinative treatment caused similar ef-
fects in cells with enforced expression of RhoA. After treating the
transfected cells with emodin in combination with ATO for 1 hour,
the level of relative ROS was increased in all three transfection
groups. Also in parallel, after treatment for 48 hours, the apoptotic
rate was significantly increased in cells exposed to the combinative
treatment in all three transfection groups. Notably, apoptosis in
V14RhoA-transfected cells was similarly enhanced, although to a
modest extent. These effects could be partially reversed by the anti-
oxidant NAC (Figure 6). To validate the redox role of emodin/arsenic
combination, we also used staurosporine in combination with H2O2;
however, the effect remained the same (data not shown). These re-
sults suggested that the combinative treatment caused oxidative stress
in SGC-7901 cells and enhanced apoptosis, during which RhoA ac-
tivation was inhibited in an ROS-dependent manner in the early
phase. These also implied that oxidative stress could overcome the
force of antiapoptosis rendered by activation of RhoA, as in V14-
transfected cells.
Figure 2. Overexpression or overactivation of RhoA in SGC-7901 cells antagonized ATO-induced apoptosis (Annexin V/PI flow cytome-
try). (A) Cells were transfected with wild-typed (WT) RhoA at increased doses and were exposed to ATO (5 μM) for 48 hours. (B) Cells
were transfected with mock DNA, V14RhoA, and N19RhoA at 40 hours before treatment with or without ATO (5 μM) for 48 hours. The
quantity of RhoA expression was controlled by Western blot analysis. Values were mean ± SD of three different experiments. ANOVA
was used for comparison of each group. *P < .05.
Figure 3. RhoA activation promoted anoikis resistance of SGC-7901 cells (colony formation in soft agar). Cells were seeded in the agar at
40 hours posttransfection and remained growing for 2 weeks before colony calculation (original magnification, ×50). Values were
mean ± SD of three different experiments. ANOVA was used for comparison of each group. *P < .05.
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Figure 4. RhoA activation changed the assembly of actin and distribution of vinculin (confocal microscopy and Western blot analysis).
Cells were assayed at 40 hours posttransfection with the vector DNA or the RhoA mutants. (A) RhoA immunofluorescence (green) and F-
actin staining with rhodamine–phalloidin (red). (B) RhoA and vinculin double immunofluorescence (red for RhoA and green for vinculin).
(C) Western blot analysis for vinculin and actin. Scale bar, 10 μm.
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Oxidative Stress Caused by Emodin in Combination with
Arsenic Could Overcome Anoikis Resistance of SGC-7901
Cells Transfected with V14RhoA
Because overactivation of RhoA promoted anoikis resistance in
V14RhoA-transfected SGC-7901 cells, we checked colony formation
of V14RhoA cells exposed to oxidative stress. Drugs or reagents were
administered for a short period (9 hours) and were rinsed off before
cells were seeded into agar and allowed to grow for 2 weeks. The
number and size of colonies were significantly decreased, compared
with those under nondrug-treated condition as in Figure 3. More im-
portantly, in the wells exposed to the combinative treatment, the
number of colonies was dramatically decreased, compared with
ATO alone treatment. This effect could be partially reversed by the
antioxidant NAC (Figure 7). Therefore, it was implied that anoikis
resistance mediated by overactivation of RhoA could be reversed by
oxidative stress.
Oxidative Stress Caused by Emodin in Combination with
Arsenic Altered Assembly of Actin and Distribution of Vinculin
How two-drug–caused oxidative stress changed actin filaments
and cell attachment was observed in the native SGC-7901 cells. In
untreated cells, the bundles of the stress fiber were assembled across
the cytoplasm, and the vinculin was distributed over the whole cyto-
plasm, but spottily concentrated at the focal adhesion sites where the
fibers terminated and actin/vinculin were well colocalized (Figure 8,
upper panel ). In the cells exposed to emodin combined with arsenic
for 12 hours (Figure 8, middle panel), the cells became detached
and finally round up in which F-actin was not assembled into the
elongated stress fibers, but rather, concentrated beneath the plasmic
membranes to form cortical rings. Meanwhile, the vinculin was dis-
persed, no longer focused at the adhesive foci. Moreover, actin
and vinculin were not colocalized anymore, especially in round
up cells that might represent apoptotic cells (lower parts of the mid-
dle panel). These effects of cotreatment were abolished by NAC (Fig-
ure 8, lower panel ).
Oxidative Stress Caused by Emodin in Combination with
Arsenic Induced Disassembly of F-Actin That Preceded
Caspase-3 Activation
To determine the temporal association of disassembly of F-actin
and apoptosis, we observed the change of assembly of F-actin and
caspase-3 activation on oxidative stress. Figure 9 illustrates the time
courses of change in caspase-3 protease activity and concomitant ac-
tin assembly pattern in SGC-7901 cells exposed to the combinative
treatment. As early as 3 hours on the combinative treatment, the
bundles of the stress fiber started to disassemble; the fibers gradually
shortened and accumulated to the cortex of the cells. At 12 hours of
Figure 5. Oxidative stress caused by emodin in combination with
arsenic suppressed the activation of RhoA, but did not downregu-
late the expression of total RhoA (DCF flow cytometry, GST-RBD
pull-down, and Western blot). (A) Relative cellular ROS level of na-
tive SGC-7901 cells after 1-hour treatments. ATO, 5 μM; Emodin,
10 μM; NAC, 10 mM. Values were mean ± SD of three different
experiments. ANOVA was applied for comparison of the means of
two groups. *P < .05. (B) Western blot for RhoA of native SGC-
7901 cells after 9-hour treatments. ATO, 5 μM; Emodin, 10 μM;
NAC, 10 mM. Blots were representative of two experiments.
Figure 6. Oxidative stress caused by emodin in combination with
arsenic-enhanced apoptosis, and these effects could be partially
reversed by NAC. (A) Relative ROS level after 1-hour treatments
in SGC-7901 cells 40 hours posttransfection with DNA for mock
and RhoA mutants: ATO, 5 μM; Emodin, 10 μM; NAC, 10 mM.
ATO versus ATO + Emodin: P < .05. (B) Apoptotic rates after
48-hour treatments in cells with transfections and treatments sim-
ilar to panel A. ATO versus ATO + Emodin: P < .05; ATO + Emo-
din versus ATO + Emodin + NAC: P < .05. Values were mean ±
SD of three different experiments. ANOVA was used for compar-
ison of each group.
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treatment, the cells rounded up and actin formed cortex rings when
caspase-3 began to be activated. Caspase-3 activity had substantial
elevation after 12 hours. These results demonstrated that oxidative
stress inhibited RhoA activation and induced F-actin disassembly,
which was followed by apoptosis.
Discussion
RhoA and Gastric Cancer
RhoA has been intensively studied for its functions in cell signal-
ing that regulates cytoskeleton-dependent responses, including cell
phagocytosis, attachment, and migration [3,5,43]. In recent years,
RhoA has been found overexpressed or overactivated in breast cancer,
bladder cancer, ovarian cancer, and other cancers [7–10]. Hence, it is
important to understand how RhoA plays a role in cancer biology
through aberrant function in regulating assembly of cytoskeleton,
i.e. actin, and cell/ECM adhesion. Here we have demonstrated in
10 normal human gastric tissues and 60 human gastric carcinoma tis-
sues by immunohistochemistry that the expression level of RhoA pro-
tein is significantly higher in gastric carcinoma cells, especially in
lowly differentiated carcinoma, than in normal gastric mucosa cells.
RhoA expression is associated with the differentiation grade, suggest-
ing that the expression level of RhoA correlated with the progressive-
ness of gastric cancer. To further explore the contribution of RhoA to
gastric cancer cells, we interfere with RhoA function in cultured
SGC-7901 cells, a cell line derived from a metastatic gastric cancer,
by transfection with the wild-typed RhoA, the constitutively active
RhoA and the dominant negative RhoA. The results reveal that both
of overexpressed and overactivated RhoA prevent gastric cancer cells
from apoptosis induced by ATO, or in fact, confer them resistance
to anoikis. These in vitro data likely reflect the biologic function of
RhoA in the primary gastric cancers.
RhoA and Anoikis
The mechanisms of anoikis involve a multitude of signal path-
ways, therefore anoikis resistance phenotype of transformed cells is
endowed by various factors. Phosphorylation regulation of some focal
adhesion proteins such as FAK and paxillin are known to be of ut-
most importance in the control of focal adhesion structure turnover
and anoikis [21,44]. Normally, FAK is stimulated by transmembrane
integrin proteins that bind to fibronectin extracellularly and (indi-
rectly) to actin filaments intracellularly. FAK, when activated by in-
tegrins, can suppress anoikis [45]. Many oncogenic growth factors,
kinases, and prosurvival transcription factors, for instance, NFκB, in-
hibit anoikis by activation of FAK, independently of integrins
[46,47]. Because the actin filaments terminate at focal adhesion,
and the integrity of focal adhesion complex requires correct organi-
zation of ECM, integrins, actin, and a series of cytoskeletal proteins,
anoikis is readily affected by the reorganization of actin that processes
RhoA modulation. However, so far, the mechanism that RhoA reg-
ulates anoikis has not drawn adequate study, although other two ma-
jor members of the Rho family, i.e., Rac1 and Cdc42, are supposed
to inhibit anoikis [48]. Recently, it has been reported that RhoA is
activated in the ethanol-induced anoikis in astrocytes [49].
Based on our findings that RhoA is upregulated in the gastric
cancer cells, and that overactivation of RhoA makes the gastric cancer
cells resistant to anoikis, we hypothesize that, in these cells, RhoA
confers anoikis resistance through, at least in part, promoting F-actin
assembly and focal adhesion formation. It is known that active
Figure 7. Oxidative stress caused by emodin in combination with arsenic inhibited anoikis resistance of SGC-7901 cells transfected with
V14RhoA (colony formation in soft agar). Cells were seeded in the agar after drug treatments for 9 hours at 40 hours posttransfection of
V14RhoA, and remained growing for 2 weeks before calculation (original magnification, ×50). ATO, 5 μM; Emodin, 10 μM; NAC, 10 mM.
Values were mean ± SD of three different experiments. ANOVA was applied for comparison of each group. *P < .05.
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RhoA can initiate the assembly of a new actin filament from actin
monomers [50], and vinculin is a key protein in focal adhesion link-
ing actin filament to integrin [23]. We found in cells where endoge-
nous RhoA activation is suppressed by the introduction of dominant
negative mutant that actin fails to organize to the fibers and that vin-
culin could not localize to focal adhesion sites. Moreover, these cells
are sensitive to the autonomous and ATO-induced apoptosis, as well
as anoikis, compared to their parental cells. In contrast, in cells bear-
ing the constitutively activated RhoA, focal adhesion is strengthened
and cells are better spreading in culture, and in addition, cells are
remarkably resistant to apoptosis and anoikis. Therefore, our study
has verified for the first time that RhoA activation is necessary for the
maintenance of anoikis resistance phenotype in cancer cells in vitro,
simultaneously suggesting that RhoA could be a useful therapeutic
target for gastric cancer. Despite that RhoA activation may result
in anoikis resistance parallel that of a non–cytoskeletal pathway, as
we also have found that NFκB activation is involved (data not
shown), the striking morphologic difference presented in the two
types of RhoA mutant–transfected cells is evidence of the predomi-
nant contribution by the cytoskeletal pathway.
It is interesting to evaluate the function of RhoA-related actin as-
sembly in mediating two opposite behaviors: anoikis resistance and
apoptotic morphologic changes. A typical morphology of apoptosis
consists of two phases: first, contraction and blebbing; and second,
breakdown of actin filaments and formation of apoptotic body. RhoA
activation is responsible for both phases of actin reorganization [3]. In
our study, by counting the apoptotic rate and colony formation in
RhoA constitutively activated cells and repressed cells, respectively,
we have revealed that RhoA activation is of antiapoptosis. It suggests
that whether RhoA is transiently activated or not during apoptosis, its
constitutive activation rescues apoptosis. It seems that the former is the
issue of form of death, and the latter is the issue of living or dead. We
then speculate that these two behaviors are controlled by entirely dif-
ferent upstream signals. The former is only triggered by irreversible
apoptotic events, for instance, activation of the executive caspases,
but the latter is concomitantly stimulated by the molecules that induce
cell transformation or by various insults that initiate apoptosis. Over-
activation of RhoA is thus one of the cancerous phenotypes.
ROS, RhoA, and Anoikis
As anoikis resistance is a hallmark of the transformed cells, it has
been well recognized that the reversion of anoikis resistance can be a
strategy to block tumor progression [20]. Meanwhile, Rho GTPases
are considered potential candidates for anticancer therapy [6,10,51].
Hence, it is demanded to develop novel drugs and approaches to re-
press Rho members that confer anoikis resistance.
Chemotherapy is the most commonly used therapeutic approach
in addition to operation for gastric cancers. Cellular redox state
Figure 8. Oxidative stress caused by emodin in combination with arsenic-altered assembly of F-actin and distribution of vinculin, espe-
cially in apoptotic cells, whereas NAC could antagonize this effect (confocal microscopy). Native SGC-7901 cells were exposed to drugs
for 12 hours. ATO, 5 μM; Emodin, 10 μM; NAC, 10 mM. Scale bar, 10 μm. Two parts of the middle panel showed cells separated in the
field with two typical morphologies of cell detachment. Cells in the upper parts of the middle panel started to detach and the lower parts
of the middle panel were round up with cortex actin rings.
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affects the cytotoxicity of a number of chemotherapeutic agents [52–
54]. We previously demonstrated that an ROS producer emodin
could strengthen ATO-induced apoptosis in a variety of cancer cells
both in culture and in tumor-bearing mice [32,33]. Here we show
that after treatment with ATO/emodin combination, the higher level
of oxidative stress triggers apoptosis of gastric cancer cells, during
which the activation of RhoA is markedly repressed at the early
phase. The decreased or diminished cell colonies formed in soft agar
have indicated cell detachment and recovery of anoikis by oxidative
stress. Further investigation for time course has demonstrated that
oxidative stress–caused disassembly of actin fibers is not a late event
secondary to apoptosis initiation, rather it precedes caspase-3 activa-
tion, providing more evidence of anoikis.
It has long been noticed that coincident with endothelial cell de-
tachment, there is a dramatic rise in the intracellular ROS level, and
reattachment to a solid surface rapidly attenuates the ROS level.
Thus, ROS are suggested to serve as regulators of anoikis [55], al-
though the signaling pathway is not clear. In contrast with the case
that ROS elevation follows detachment of endothelial cells, in out
study, ROS likely initiates detachment through suppressing RhoA
to abrogate anoikis resistance of gastric cancer cells.
As a key modulator of cell response to various stimuli, RhoA may
be activated by a modest oxidative stress [35]. Conversely, it is inac-
tivated by a severe oxidative stress due to oxidative modification of
the specific cysteine residues [34], despite that transit activation may
be observed during the progress, which makes researchers draw the
controversial claims in respect to ROS–RhoA and RhoA–apoptosis
associations [49,56]. In our previous studies, we have found that
multiple proteins, including NFκB and caspase-9, undergo oxidative
modification in the emodin-caused redox stress, resulting in differen-
tial switch of molecular activity [33]. Whether RhoA is oxidatively
modified and what the responsible cysteine site(s) are under our experi-
mental conditions are issues for future investigation. In addition to the
proposal that RhoA is a novel target regulated by oxidative stress,
the present study has suggested that emodin might be an inhibitor of
RhoA with therapeutic benefit, especially when applied in synergy with
other anticancer drugs.
In conclusion, we provide evidence that the inhibition of RhoA by
a high oxidative stress induces anoikis; that is, apoptosis caused by
lack of correct cell/ECM attachment. As proposed in our model (Fig-
ure 10), RhoA inactivation by ROS leads to the actin filaments’ dis-
ruption, and consequently followed by vinculin mislocalization,
which triggers structural changes in focal adhesion and eventually re-
sults in anoikis. As the basis of this viewpoint, active RhoA is re-
quired for antianoikis. The regulatory role of other proteins of
focal adhesion that are probably involved in RhoA-mediated anoikis
resistance, for instance, vinculin, is worth exploring.
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Figure W1. The increase of RhoA expression in the transfected cells shown by Western blots in Figure 2, A and B was verified by semi-
quantitative assays using a Zeiss KS400 (Version 2.2). The gray level of the RhoA bands (upper panel) were normalized by the β-actin
ones (lower panel), and the quantitative data was shown by the bar charts.
